RAGE receptor targeted bioconjuguate lipid nanoparticles of diallyl disulfide for improved apoptotic activity in triple negative breast cancer: in vitro studies
Source abstract
Abstract
In the present study, we have demonstrated receptor for advanced glycation endproducts (RAGE) as a target for delivery of drugs specifically to triple negative breast cancer cells. We have prepared solid lipid nanoparticle formulation of cytotoxic agent di-allyl-disulfide (DADS) to overcome its bioavailability issues. Then, we have surface modified DADS-loaded solid lipid nanoparticles (DADS-SLN) with RAGE antibody to achieve site-specific delivery of DADS to TNBC cells. We found a significant cellular internalization of RAGE surface modified DADS-SLN (DADS-RAGE-SLN) when compared to DADS-SLN. The cytotoxic effect of DADS was also significantly improved with DADS-RAGE-SLN by downregulating anti-apoptotic proteins and upregulating pro-apoptotic proteins as observed by western blot analysis. RAGE-targeted delivery of cytotoxic agents can be, therefore, a promising approach for improving antitumour activity and reducing off-target effects.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advanced Glycation End Products research · Sesame and Sesamin Research · Phytochemicals and Antioxidant Activities
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmaceutics, JSS College of Pharmacy, Udhagamandalam (Jagadguru Sri Shivarathreeshwara University), Tamil Nadu, India;
Department of Pharmacology, JSS College of Pharmacy, Udhagamandalam (Jagadguru Sri Shivarathreeshwara University), Tamil Nadu, India;
Department of Pharmaceutics, GIET School of Pharmacy, Rajahmundry, Andhra Pradesh, India
References (34)
Show source-provided references
1. 10.1038/3502109310.1038/35021093 ↗
2. 10.1200/JCO.2005.03.384510.1200/JCO.2005.03.3845 ↗
3. 10.3390/nu311096210.3390/nu3110962 ↗
4. 10.1038/modpathol.2010.20010.1038/modpathol.2010.200 ↗
5. 10.1016/S0959-8049(09)70012-710.1016/S0959-8049(09)70012-7 ↗
6. 10.1080/0735790070178423810.1080/07357900701784238 ↗
7. 10.3390/ijms1404795910.3390/ijms14047959 ↗
8. 10.1016/j.mehy.2007.12.01810.1016/j.mehy.2007.12.018 ↗
9. 10.1002/path.428010.1002/path.4280 ↗
10. 10.1016/S0021-9258(18)42138-210.1016/S0021-9258(18)42138-2 ↗
11. 10.1016/S0006-291X(03)01190-210.1016/S0006-291X(03)01190-2 ↗
12. 10.1016/j.bbamcr.2008.11.01610.1016/j.bbamcr.2008.11.016 ↗
13. 10.1038/ncpendmet078610.1038/ncpendmet0786 ↗
14. 10.1007/s11010-013-1680-010.1007/s11010-013-1680-0 ↗
15. 10.1158/0008-5472.CAN-14-216110.1158/0008-5472.CAN-14-2161 ↗
16. 10.2337/diabetes.50.6.149510.2337/diabetes.50.6.1495 ↗
17. 10.1016/j.bbagen.2013.11.01410.1016/j.bbagen.2013.11.014 ↗
18. 10.3109/21691401.2016.117304610.3109/21691401.2016.1173046 ↗
19. 10.1080/10717544.2016.119960610.1080/10717544.2016.1199606 ↗
20. 10.1371/journal.pone.003292010.1371/journal.pone.0032920 ↗
21. 10.1016/j.ijpharm.2008.06.00210.1016/j.ijpharm.2008.06.002 ↗
22. 10.2174/156720181166614041411525910.2174/1567201811666140414115259 ↗
23. Talluri S · 2016 · 57
24. 10.1016/j.colsurfb.2005.08.00510.1016/j.colsurfb.2005.08.005 ↗
25. Zhang L · Int J Nanomedicine · 2015 · 10 · 2101
26. 10.1007/s11095-014-1504-210.1007/s11095-014-1504-2 ↗
27. 10.1038/nprot.2006.17910.1038/nprot.2006.179 ↗
28. 10.3109/10717544.2014.88244610.3109/10717544.2014.882446 ↗
29. Vaupel P · Cancer Res · 1989 · 49 · 6449
30. 10.1096/fj.02-0088com10.1096/fj.02-0088com ↗
31. Gabizon AA. · Cancer Res · 1992 · 52 · 891
32. 10.1016/j.toxlet.2012.10.00810.1016/j.toxlet.2012.10.008 ↗
33. 10.1111/j.1742-4658.2009.07329.x10.1111/j.1742-4658.2009.07329.x ↗
34. 10.4174/jkss.2011.81.2.8510.4174/jkss.2011.81.2.85 ↗